Crucell N.V. Announces Start of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US; First Milestone Achieved in Collaboration Agreement with Sanofi Pasteur

Leiden, The Netherlands, 31 March 2008 - Dutch biotechnology company Crucell N.V. today announced that its rabies monoclonal antibody combination has entered a Phase II clinical trial in the United States. At the beginning of the year, Crucell announced it had signed a collaboration and commercialization agreement with sanofi pasteur, the vaccines division of sanofi-aventis Group, for Crucell's rabies monoclonal antibodies to be used in combination with sanofi pasteur rabies vaccine for post-exposure prophylaxis against this fatal disease. The start of the Phase II study constitutes the first milestone in this agreement.